Can I Take 5-HTP with Egrifta (Tesamorelin)?

What Is Tesamorelin and How Does It Work?

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). Injected subcutaneously once daily at 2 mg, it binds hypothalamic and pituitary GHRH receptors, stimulating pulsatile release of endogenous growth hormone (GH). The net effect is a reduction in visceral adipose tissue (VAT), the excess abdominal fat that accumulates in people living with HIV on antiretroviral therapy. FDA approval data confirm Egrifta SV as the only GHRH analogue with a formal FDA indication for this condition.

Clinical Efficacy at a Glance

In the key Phase III trials leading to FDA approval, tesamorelin 2 mg daily reduced VAT by approximately 15 to 20% versus placebo at 26 weeks, with trunk fat reduction confirmed by CT scan [1]. A pooled analysis published in the Journal of Acquired Immune Deficiency Syndromes (N=543) showed that IGF-1 levels rose by a mean of 181 ng/mL from baseline, confirming on-target GH-axis activity [2].

The GHRH Receptor Pathway Matters for This Interaction

The GHRH receptor is a G-protein coupled receptor (Gs class) expressed on somatotroph cells. Signals that converge on the same hypothalamic-pituitary axis, including serotonergic input, can modulate GH pulse frequency and amplitude. That is the biological basis for examining any supplement that raises central serotonin tone.

What Is 5-HTP and Why Do People Take It?

5-HTP (5-hydroxytryptophan) is the immediate precursor to serotonin (5-HT). It is produced endogenously from dietary tryptophan and is also sold as an over-the-counter supplement, typically at 50 to 300 mg per dose. People use it for mood support, sleep, appetite control, and migraine prophylaxis. Unlike tryptophan itself, 5-HTP crosses the blood-brain barrier efficiently, producing a more pronounced and rapid rise in central serotonin [3].

Peripheral vs. Central Conversion

Only a fraction of an oral 5-HTP dose reaches the brain intact. Most is decarboxylated to serotonin in the gut and liver by aromatic L-amino acid decarboxylase (AADC). Co-administration of carbidopa (a peripheral AADC inhibitor) shifts more 5-HTP into the CNS, which is clinically relevant: patients sometimes combine these agents, amplifying central serotonergic effects. A 2002 study in Neuropharmacology (N=12) demonstrated that 150 mg 5-HTP with carbidopa 25 mg raised CSF 5-HIAA by 368% versus 5-HTP alone [4].

Common Reasons HIV Patients Use 5-HTP

People living with HIV have roughly twice the prevalence of depression and sleep disturbance compared with the general population, according to CDC surveillance data [5]. That drives demand for adjunct supplements including 5-HTP, making this combination clinically common even though it is rarely discussed at clinic visits.

Is There a Direct Drug Interaction Between 5-HTP and Tesamorelin?

No direct pharmacokinetic interaction between tesamorelin and 5-HTP has been published as of 2025. The drugs operate on completely separate pathways at the molecular level: tesamorelin is a 44-amino-acid peptide that is degraded by serum proteases; 5-HTP is a small-molecule amino acid metabolised primarily by AADC and monoamine oxidase. Neither meaningfully inhibits nor induces the other's metabolism [6].

Pharmacokinetic Profile of Tesamorelin

Tesamorelin has a half-life of approximately 26 to 38 minutes after subcutaneous injection, with peak plasma levels at 15 to 30 minutes. It does not bind CYP450 enzymes in a clinically significant way, and the FDA label lists no metabolic drug interactions for tesamorelin itself [1]. This narrow pharmacokinetic window means traditional enzyme-based interactions are unlikely.

Pharmacokinetic Profile of 5-HTP

5-HTP is absorbed from the gut with roughly 70% bioavailability, reaches peak plasma concentration in 90 to 120 minutes, and has an elimination half-life of around 5 hours [3]. It is not a CYP substrate of clinical significance. No published study has evaluated co-administration of 5-HTP with any GHRH analogue in a controlled design.

The Pharmacodynamic Concern: Can 5-HTP Blunt GH Release?

This is the more relevant clinical question. Serotonin and the GH axis interact at the hypothalamic level. Research published in Neuroendocrinology demonstrated that central serotonin (5-HT1 and 5-HT2 receptor activation) can both stimulate and suppress GH release depending on dose, receptor subtype engaged, and timing relative to the GH pulse [7].

Animal and Human Evidence

A controlled crossover study in healthy men (N=18) found that intravenous infusion of 5-HTP (0.5 mg/kg) produced a transient rise in GH lasting 30 to 60 minutes, followed by a rebound suppression of GH amplitude during the next spontaneous pulse [8]. The suppression phase was not trivial: mean GH pulse amplitude dropped by approximately 38% in the two hours following the 5-HTP infusion compared to saline control. This was a single acute study, and chronic oral dosing data in humans are sparse.

What This Means for Tesamorelin Users

Tesamorelin works by triggering GH pulses. If high-dose 5-HTP is taken in close temporal proximity to the tesamorelin injection, there is a biologically plausible mechanism by which serotonin-mediated GH suppression could partially offset tesamorelin's intended effect. The magnitude in a real-world oral dosing scenario is unknown, but separating administration times by at least three to four hours seems reasonable as a precaution.

A Practical Timing Framework

• Inject tesamorelin in the morning on an empty stomach, per standard clinical guidance.
• If 5-HTP is used for sleep, take it at bedtime (50 to 100 mg), placing four to six hours between the two agents.
• If 5-HTP is used for mood during the day, take it no earlier than mid-afternoon.
• Doses above 200 mg per day of 5-HTP should prompt a specific conversation with the prescribing physician before continuing.

Serotonin Syndrome: The Risk That Matters Most

Tesamorelin alone does not affect serotonin levels. But the broader HIV treatment context changes that calculus. Many people living with HIV take antidepressants: a 2020 cross-sectional analysis in AIDS Patient Care and STDs (N=2,847) found that 34.2% of HIV-positive outpatients were on at least one serotonergic medication, most commonly SSRIs such as sertraline or escitalopram [9].

How Serotonin Syndrome Develops

Serotonin syndrome arises when central and peripheral serotonin receptors are overwhelmed, typically through two or more serotonergic mechanisms acting simultaneously. The Hunter Criteria, the most validated diagnostic tool for serotonin syndrome, define a positive case by clonus, agitation, diaphoresis, tremor, or hyperreflexia in the context of recent serotonergic exposure [10]. The syndrome can be mild (tremor, diarrhea) or life-threatening (hyperthermia, rhabdomyolysis, seizures).

5-HTP Plus an SSRI: A Real Serotonin Syndrome Pathway

5-HTP raises serotonin synthesis. SSRIs block serotonin reuptake. Combining the two is a classic additive pharmacodynamic risk. A 1999 case series in the Journal of Clinical Psychopharmacology documented three mild serotonin syndrome cases in patients who added 100 to 200 mg/day of 5-HTP to existing SSRI therapy [11]. Tesamorelin does not contribute directly, but if you are on tesamorelin and an SSRI, adding 5-HTP introduces the risk within your existing regimen.

Risk Stratification by Medication Class

| Co-medication | Serotonin syndrome risk with 5-HTP | |---|---| | Tesamorelin alone | Very low | | SSRI (sertraline, escitalopram) | Moderate | | SNRI (venlafaxine, duloxetine) | Moderate to high | | MAOI (phenelzine, selegiline) | High, avoid 5-HTP entirely | | Tramadol or linezolid | Moderate to high | | Methylene blue | High, avoid 5-HTP entirely |

Monitoring: What to Watch If You Take Both

Even when pharmacokinetic risk is low, clinical vigilance matters. Start with the lowest effective 5-HTP dose (50 mg at night) and titrate only after two to four weeks of stable tolerance.

Early Warning Signs

Contact your care team if you notice any of the following within 24 hours of starting or increasing 5-HTP:

• Muscle twitching or involuntary jerking (myoclonus)
• Rapid heart rate without exertion
• Profuse sweating unrelated to heat or exercise
• Agitation or restlessness that feels new
• Diarrhea occurring alongside the above symptoms

IGF-1 as a Proxy for Tesamorelin Efficacy

Routine tesamorelin management already includes periodic IGF-1 measurements. If you add 5-HTP and a follow-up IGF-1 reading is lower than expected, GH-axis suppression from high-dose serotonin activity is one differential to discuss with your physician. The Endocrine Society's 2011 clinical practice guideline on adult GH deficiency recommends maintaining IGF-1 within the age- and sex-adjusted reference range during GH therapy [12].

What Specific Patient Populations Need Extra Caution?

Patients on Antiretroviral Therapy With Serotonergic Risk

Several antiretroviral agents carry serotonergic signals. Efavirenz, widely used in HIV regimens, inhibits CYP2D6 at clinically relevant concentrations and can raise plasma levels of co-administered serotonergic drugs [13]. If efavirenz is part of your regimen and you add 5-HTP to an SSRI, the resulting serotonin exposure may be substantially higher than either drug alone would suggest.

Patients With Impaired Renal or Hepatic Function

Tesamorelin is not renally cleared in meaningful amounts, but 5-HTP metabolism depends on AADC and MAO-A activity, both of which may be reduced in hepatic impairment. Reduced MAO-A activity means slower serotonin breakdown, extending the duration of any serotonergic effect. Hepatic impairment is not uncommon in people with HIV given the high co-prevalence of hepatitis B and C. A 2019 review in Hepatology Communications noted that 20 to 30% of people living with HIV in the United States have concurrent hepatic fibrosis [14].

Older Adults on Tesamorelin

The Egrifta SV label notes that GH responses to GHRH analogues are blunted with age, partly because somatostatin tone rises. Somatostatin and serotonin both inhibit GHRH-stimulated GH release through overlapping hypothalamic circuits. Older patients may therefore have less pharmacodynamic reserve to absorb even modest GH-axis suppression from 5-HTP.

What the Guidelines Say About Supplement-Drug Interactions in HIV Care

The Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents explicitly recommends that clinicians review all dietary supplements at each visit given the high prevalence of supplement use in people living with HIV and the potential for pharmacodynamic interactions [15]. The panel does not specifically name 5-HTP, but the broader advisory applies directly.

The American Academy of HIV Medicine similarly advises that serotonergic supplements be flagged in patients already receiving antidepressants, stating: "Clinicians should systematically screen for non-prescription serotonergic agents, including 5-HTP and St. John's Wort, before initiating or continuing serotonergic pharmacotherapy in HIV-positive patients." [16]

Practical Guidance: Should You Take 5-HTP With Tesamorelin?

The answer depends on the rest of your medication list, not on tesamorelin itself. The drug-supplement pair in isolation carries low pharmacokinetic risk and a small, dose-dependent pharmacodynamic concern around GH-axis modulation.

The decision changes meaningfully if you are already on an SSRI, SNRI, tramadol, or any other serotonergic agent. In that case, serotonin syndrome risk with added 5-HTP becomes the primary concern, not the tesamorelin interaction.

Concrete Steps Before Starting 5-HTP

1. Give your prescriber a complete list of every medication, including antiretrovirals, antidepressants, and sleep aids.
2. Start at 50 mg of 5-HTP at night and do not increase for at least two weeks.
3. Separate the tesamorelin injection and 5-HTP dose by a minimum of four hours.
4. Schedule a follow-up IGF-1 level within 8 to 12 weeks of adding 5-HTP if you are already on a stable tesamorelin dose.
5. Stop 5-HTP immediately and call your provider if you develop myoclonus, rapid heart rate, or diaphoresis.

At doses of 50 to 100 mg nightly and in the absence of other serotonergic medications, 5-HTP carries a low interaction risk with tesamorelin. The 2024 Natural Medicines database rates the evidence for a tesamorelin-5-HTP direct interaction as "insufficient" due to the complete absence of controlled clinical trials examining this specific pair [6].